Evenity (romosozumab)
- Region
- 🇪🇺 EU
- Active substance
- romosozumab
- Company
- UCB Pharma S.A.
- Status
- Authorised
- Therapeutic area
- Osteoporosis
- EU approval
- Mon 09 Dec 2019
- Application
- EMEA/H/C/004465
- ATC
- M05BX
- Official record
- www.ema.europa.eu
Indication
Evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Regulatory milestones
No milestones recorded in the last year.
Follow Evenity
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.